{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:06:49Z","timestamp":1788667609618,"version":"build-2803163510"},"reference-count":19,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"25","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Lipophilic drugs, such as taxanes, have a high affinity for adipose tissue and a resulting higher volume of distribution. Here, we reanalyzed clinical trial data to investigate whether the efficacy of docetaxel-based chemotherapy differs from non-docetaxel\u2013based chemotherapy in patients with breast cancer according to their baseline body mass index (BMI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed data from all of the patients in the adjuvant BIG 2-98 trial (ClinicalTrials.gov identifier: NCT00174655 ; N = 2,887) comparing non-docetaxel\u2013 to docetaxel-containing chemotherapy. BMI (kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) was categorized as follows: 18.5 to &lt; 25, lean; 25 to &lt; 30, overweight; and \u2265 30, obese. Disease-free survival (DFS) was the primary endpoint, and overall survival (OS) was the secondary endpoint. A second-order interaction was assessed among treatment, BMI, and estrogen receptor (ER) status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>There was no difference in DFS or OS according to BMI in the non-docetaxel group, while reduced DFS and OS were observed with increasing BMI category in the docetaxel group. Adjusted hazard ratios for DFS and OS were, respectively, 1.12 (95% CI, 0.98 to 1.50; P = .21) and 1.27 (95% CI, 1.01 to 1.60; P = .04) for overweight versus lean groups and were 1.32 (95% CI, 1.08 to 1.62; P = .007) and 1.63 (95% CI, 1.27 to 2.09; P &lt; .001), respectively, for obese versus lean groups. Similar results were obtained when considering ER-negative and ER-positive tumors separately and when considering only patients who received a relative dose intensity \u2265 85% for docetaxel. A joint modifying role of BMI and ER status on treatment effect was evident for DFS (adjusted P = .06) and OS (adjusted P = .04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>This retrospective analysis of a large adjuvant trial highlights a differential response to docetaxel according to BMI, which calls for a body composition\u2013based re-evaluation of the risk-benefit ratio of the use of taxanes in breast cancer. These results now must be confirmed in additional series.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.19.01771","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T16:00:16Z","timestamp":1593705616000},"page":"2883-2891","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":57,"title":["Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index"],"prefix":"10.1200","volume":"38","author":[{"given":"Christine","family":"Desmedt","sequence":"first","affiliation":[{"name":"Laboratory for Translational Breast Cancer Research, Department of Oncology, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fornili","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics, Biometry and Bioinformatics Giulio A. Maccacaro Department of Clinical Sciences and Community Health & DSRC, University of Milan, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Clatot","sequence":"additional","affiliation":[{"name":"Laboratory for Translational Breast Cancer Research, Department of Oncology, Leuven, Belgium"},{"name":"Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Demicheli","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics, Biometry and Bioinformatics Giulio A. Maccacaro Department of Clinical Sciences and Community Health & DSRC, University of Milan, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"De Bortoli","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics, Biometry and Bioinformatics Giulio A. Maccacaro Department of Clinical Sciences and Community Health & DSRC, University of Milan, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Di Leo","sequence":"additional","affiliation":[{"name":"Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Instituto Toscano Tumori, Prato, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[{"name":"European Institute of Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[{"name":"Breast European Adjuvant Study Team, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Crown","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence A.","family":"Francis","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, St Vincent\u2019s Hospital, University of Melbourne, Australia; Breast Cancer Trials Australia and New Zealand, University of Newcastle, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Sotiriou","sequence":"additional","affiliation":[{"name":"Breast Cancer Translational Lab, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[{"name":"Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Biganzoli","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics, Biometry and Bioinformatics Giulio A. Maccacaro Department of Clinical Sciences and Community Health & DSRC, University of Milan, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30054-X"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.4480"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1606602"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5327"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1021\/js980173a"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-014-0107-x"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm287"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.03.018"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4436"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.002"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7614"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh222"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv179"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0512-0"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.2938"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3572"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.11.013"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1088-6"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.01771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T05:53:06Z","timestamp":1653803586000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.01771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":19,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["10.1200\/JCO.19.01771"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.01771","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"2020-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}